

## Borja Ibanez, MD PhD



Borja Ibáñez (Madrid, 1975) combines research activities as Group Leader at the CNIC with clinical activities as interventional cardiologist at the University Hospital Fundación Jiménez Díaz. He is also Director of the Clinical Research Department at CNIC. He is Group Leader at CIBERCV network.

He was trained in Spain and in USA (Mount Sinai Heart, NY). His research is at the verge of basic and clinical arena, mainly in the fields of MI, heart failure and lately to cancer therapy-induced cardiotoxicity. He is an advanced imaging user, and has used magnetic resonance imaging to better understand pathophysiology of myocardial diseases (tissue characterization) and to evaluate the benefits of cardioprotective therapies. He actively participates in primary prevention studies focused on atherosclerosis early identification by imaging to improve risk prediction.

He is PI of several multicenter clinical trials recruiting patients with myocardial infarction and heart failure, including the megatrial REBOOT, which already recruited more than 6000 post-MI patients in Europe.

He served as the Chairman of the 2017 European Society of Cardiology (ESC) STEMI Clinical Practice Guidelines.

He is PI coordinator of several national and international projects, including H2020-funded grants, highlighting an active ERC consolidator grant called “MATRIX” (Novel mitochondria-targeted therapies for anthracycline-induced cardiotoxicity), and a H2020-HEALTH project called “RESILIENCE”. The latter is a 6M € grant devoted to test a novel cardioprotective intervention (remote ischemic conditioning) in cancer patients at risk for anthracycline-induced cardiotoxicity.

He has published more than 300 scientific publications in high-impact journals. As corresponding author, he has published top articles in basic research journals (such as Science, Nature Communications, Circ Res), and top articles in clinical research journals (such as NEJM, Lancet, Circulation, JACC, EHJ, etc). His H-index (scholar) is 65, and his works have received more than 32,000 citations.

He has received numerous awards for his scientific merits, including the Banco de Sabadell, Constantes y Vitales, Princesa de Girona, and Fundación Jesús Serra among others.

He participates in peer review activities, including being associated editor of JACC and EHJ Acute Cardiovascular Care, and member of the editorial board of several top cardiovascular journals.

Inventor of several patents, some in the field of CMR. One of these patents (ultrafast CMR) will become a clinical product during this year.